Explore the necessity for high precision in drug delivery, especially in administering highly concentrated medications for conditions like neonatal care, where even slight deviations in flow rate can have severe consequences.
To address such risks, infusion pumps undergo rigorous type testing, including flow rate assessments using the gravimetric method outlined in standards like IEC 60601-2-24:2012 and AAMI TIR-101. This article discusses the challenges faced by balances in gravimetric testing, such as accurately detecting minimal motor movements at low flow rates and ensuring rapid response and precise data acquisition at high flow rates.
Discover the crucial role of accurate medication dosages in patient care, highlighting the significance of advanced lab balances in ensuring dosing accuracy verification.
This article highlights the Sartorius Cubis® II Balances in collaboration with B.Braun, outlining optimal configurations, prevalent error sources, and prevention strategies. It underscores the evolving demands for precision in medical devices like infusion pumps, noting significant improvements in dosing accuracy, with infusion pumps achieving nanoliter-range precision.
Key takeaways:
- Requirements for the balances
- Frequent sources of error
- The setting of the balances
- Presentation of the relevant standards and norms
- Applications (insulin pumps, dosing pumps,
- micropumps)
- Challenges with flow rates from µL/hour to L/hour
Download the full white paper to learn more
About Sartorius Lab Instruments GmbH & Co. KG
The Sartorius Group is a leading international partner of life science research and the biopharmaceutical industry.
With innovative laboratory instruments and consumables, the Group’s Lab Products & Services Division concentrates on serving the needs of laboratories performing research and quality control at pharma and biopharma companies and those of academic research institutes.
The Bioprocess Solutions Division with its broad product portfolio focusing on single-use solutions helps customers to manufacture biotech medications and vaccines safely and efficiently. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies.
In fiscal 2021, the company earned sales revenue of some 3.45 billion euros. At the end of 2021, nearly 14,000 people were employed at the Group’s approximately 60 manufacturing and sales sites, serving customers around the globe.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.